AMERI Holdings (AMRH) – PRNewswire
-
Ameri Holdings Completes Spin-Off and Tender Offer, Changes Name to Enveric Biosciences and Begins Trading on the Nasdaq Under the Symbol "ENVB"
-
AMERI Holdings Announces 1-for-4 Reverse Stock Split
-
AMERI Holdings' Stockholders Approve All Proposals To Complete Tender Offer For Jay Pharma Shares
-
AMERI Holdings Adjourns Special Stockholder Meeting To December 29th
-
AMERI Holdings Announces S-4 Has Been Declared Effective
-
AMERI Holdings Files Amended Registration Statement On Form S-4
-
AMERI Holdings Files Second Amendment To Registration Statement On Form S-4
-
AMERI Holdings Files Amended Registration Statement On Form S-4
-
Jay Pharma to File IND Applications to FDA for a clinical study of proprietary formulations in Radiodermatitis and a combination Therapy in Glioblastoma
-
Ameri Holdings Provides Update On Pending Transaction With Jay Pharma Inc.
-
AMERI Holdings Announces Pricing Of $1.725 Million Registered Direct Offering Priced At-The-Market
-
AMERI Holdings Amalgamation Partner Jay Pharma Reports IRB Approval For Testing Proprietary CBD Formulation In Brain Cancer
-
Jay Pharma Details Business and Clinical Trials Strategy
-
Jay Pharma Appoints Former Mallinckrodt plc Executive as Audit Committee Chair
-
Sara Dakar to Join Jay Pharma as Vice President, Product Development
-
Former CIA Director R. James Woolsey Joins AMERI Holdings As Strategy Consultant, Expects To Join Jay Pharma Board Of Directors Upon Closing Of Merger
Back to AMRH Stock Lookup
